CJC-1295 (No DAC) & Ipamorelin Blend – 10mg/15mg (25mg Total)

This blend combines CJC-1295 (No DAC), a modified GHRH (1-29) analog, with Ipamorelin, a selective pentapeptide growth hormone secretagogue, in a single lyophilized vial at a 10mg/15mg ratio. The combination is studied to examine two distinct, complementary receptor pathways involved in growth hormone regulation within a single research formulation.

Mechanism & Research Rationale:

CJC-1295 No DAC is a GHRH (growth hormone-releasing hormone) analog with enhanced α-helical structure, studied for its activity at the GHRH receptor pathway, while Ipamorelin is a selective GHRP studied for its activity at the ghrelin receptor (GHS-R1a). The rationale for combining them stems from research examining how GHRH and GHRP pathways interact through distinct receptors and intracellular signaling cascades, allowing the two peptides to serve as a model for studying complementary signaling mechanisms simultaneously.

Key Research Areas:

• Growth Hormone Signaling Dynamics — Research models examine the interaction between GHRH and ghrelin receptor pathways and their respective roles in growth hormone-related signaling.
• Pituitary Somatotroph Signaling — CJC-1295 engages the GHRH receptor’s Gs-protein/adenylyl cyclase/cAMP/PKA pathway, while Ipamorelin engages the ghrelin receptor’s Gq-protein/calcium/PKC pathway — two mechanistically distinct downstream cascades studied in relation to pituitary signaling.
• Selective Receptor Research — Ipamorelin’s research profile includes investigation of its receptor selectivity and associated molecular signaling characteristics relative to other GHRP-class compounds.
• Short-Acting Pharmacokinetics — The No-DAC variant is used in research settings because of its shorter receptor engagement window compared with long-acting (DAC) formulations, allowing investigators to study timing-dependent signaling events.

Product Specifications:

• CJC-1295 (No DAC): 10mg | Sequence: [D-Ala²,Ala⁸,⁹,¹⁵]GHRH-(1-29)NH₂ | 29 amino acids | MW ~3,368.7 g/mol
• Ipamorelin: 15mg | Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | 5 amino acids | MW ~711.9 g/mol
• 25mg total lyophilized powder per vial
• ≥99% purity, third-party COA available (mass spectrometry recommended to confirm CJC-1295 identity vs. sermorelin)
• Store refrigerated (2–8°C); protect from light and moisture

For laboratory and research use only. Not intended for human or animal consumption, diagnostic, or therapeutic use. Not a drug, dietary supplement, or cosmetic. Not FDA-approved.